Last reviewed · How we verify
NCT04681313
Pressure-Volume Loop During High-Risk PCI
trial testing High-risk percutaneous coronary intervention in Coronary Artery Disease in 10 participants. Completed in 12 September 2024.
1 December 2022
Quick facts
| Lead sponsor | Henry Ford Health System |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 10 |
| Start date | 19 April 2021 |
| Primary completion | 1 December 2022 |
| Estimated completion | 12 September 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- High-risk percutaneous coronary intervention
Conditions studied
- Coronary Artery Disease — all drugs for Coronary Artery Disease →
Sponsor
Henry Ford Health System — full company profile →
Who can join
18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will examine the physiologic effects on loading conditions and contractility of the left ventricle during high-risk primary coronary intervention (HRPCI) in the Cardiac Cath Lab. This will be performed through analysis of real-time left ventricular (LV) pressure-volume loops (PVL) by continuously recording PVL during HRPCI with the Inca® Pressure-Volume Loop System that will be temporarily placed in the left ventricle during the procedure.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04681313
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Artery Disease
Currently open trials in the same condition.
- NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
- NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
- NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
- NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
- NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting
Other Henry Ford Health System trials
Trials by the same sponsor.
- NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
- NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
- NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
- NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
- NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04681313 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04681313.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing